findmyKOL

Stephen Wiviott, MD

Enriched profile

Associate Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group · Brigham and Women's Hospital

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLfindmyKOL type: EliteLatest publication2022Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Stephen Wiviott is Associate Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group at Brigham and Women's Hospital. ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 14 Oct 2026

Stephen Wiviott, MD, is Associate Professor of Medicine, Harvard Medical School at Brigham and Women's Hospital. The public record shows 360 publications with 70,538 citations (h-index 83), centered on Cardiology. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies.

  • Top research focus: Cardiology
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Research focus

OpenAlex concept fingerprint
Cardiology

Drugs & molecules

across trials, industry payments and publications
Nexletolgeneric · Bempedoic acidClinical trials—Industry payments1Publications—Nexlizetgeneric · Bempedoic acid / ezetimibeClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Merck Sharp & Dohme LLCClinical trials—Industry payments47Siemens Medical Solutions USA, Inc.Clinical trials—Industry payments4AstraZenecaClinical trials1Industry payments—Esperion Therapeutics, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
83h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
3companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    79.1%
    Statin19.3%
    Atorvastatin Calcium50%Rosuvastatin Calcium50%
    Part D<11 patients
    Beta blocker16.9%
    Metoprolol Succinate64%Carvedilol36%
    Part D<11 patients

    + 7 more classes in this area

  • Blood & clotting

    14.9%
    Factor Xa inhibitor8.8%
    Eliquis100%
    Part D<11 patients
    P2Y12 inhibitor6%
    Clopidogrel100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    6%
    SGLT2 inhibitor6%
    Jardiance100%
    Part D<11 patients
Where care is delivered (Part B)96.7% facility · 3.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    discoverbrigham.org

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →discoverbrigham.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →discoverbrigham.org ↗

Editorial & leadership roles

journal and society appointments
  • Fellow

    American College of Cardiology (FACC)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →discoverbrigham.org ↗
  • Chairman

    Clinical Events Committee, TIMI Study Group

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →radcliffecardiology.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.